thebiostories

Phase 1 Clinical Trials of MK-7602: A Promising New Chapter in the Fight Against Malaria ⏱ In 30 Seconds ✓ MK-7602 is a first-in-class experimental antimalarial drug jointly developed by WEHI and MSD . ✓ It blocks two essential malaria parasite enzymes, plasmepsin IX and plasmepsin X . ✓ Phase 1 studies found that MK-7602 was generally well tolerated in healthy volunteers and reached blood concentrations predicted to have antimalarial activity. ✓ The results mark an important transition from nearly a decade of laboratory research to early clinical development. From Laboratory Discovery to Human Trials For decades, malaria parasites have repeatedly evolved resistance to medicines that once transformed global malaria control, creating an urgent need for drugs that attack the parasite through entirely different biological mechanisms. In March 2026, researchers at the Walter and Eliza Hall Institute of Medical Research (WEHI) reported an important milestone in...

How WEHI Scientists Are Helping Defeat Malaria: From Fundamental Discovery to New Treatments ⏱ In 30 Seconds ✓ Malaria remains a major global health threat because parasites and mosquitoes continue to evolve resistance to existing control measures. ✓ For more than three decades, WEHI scientists have studied how malaria parasites invade, survive and reproduce inside human cells. ✓ These fundamental discoveries have revealed new biological vulnerabilities that can guide the development of medicines and vaccines. ✓ One result of this long research journey is MK-7602 , a first-in-class experimental antimalarial drug that has progressed into human clinical trials. Why Malaria Still Matters Malaria has been one of humanity’s deadliest infectious diseases for thousands of years. Although remarkable progress has been made over the past two decades, the disease still causes hundreds of thousands of deaths each year, with young children in sub-Saharan Africa carrying th...